^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ASC61
i
Other names: ASC61, ASC 61, ASC-61
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Ascletis
Drug class:
PD-L1 inhibitor
Related drugs:
8ms
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=16, Recruiting, Gannex Pharma Co., Ltd. | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date • Metastases
|
ASC61
1year
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=16, Recruiting, Gannex Pharma Co., Ltd. | Trial completion date: Mar 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
ASC61
2years
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=16, Recruiting, Gannex Pharma Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
PD-L1 (Programmed death ligand 1)
|
ASC61
over2years
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=16, Not yet recruiting, Gannex Pharma Co., Ltd. | Initiation date: Mar 2022 --> Jul 2022
Trial initiation date
|
PD-L1 (Programmed death ligand 1)
|
ASC61
over2years
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=16, Not yet recruiting, Gannex Pharma Co., Ltd.
New P1 trial
|
PD-L1 (Programmed death ligand 1)
|
ASC61
Share via
